Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  ganciclovir
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 26 for your search:
Start Over
Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 16 and over
Sponsor: NCI, Other
Protocol IDs: 1577.00, FHCRC-1577.00, MSKCC-01127, NCI-H01-0072, NCT00016068
Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CM-2008-01, 08/H0720/15, 74928896, NCT01077908
Phase I/II Study of Stereotactic Injection of the Herpes Simplex Thymidine Kinase Gene Followed by Intravenous Ganciclovir for Recurrent Malignant Glioma (Summary Last Modified 06/97)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: over 18
Sponsor: Other
Protocol IDs: UCMC-95-3-20-2, NCI-V95-0681
Phase I/II Study of In Vivo Tumor Transduction with the Herpes Simplex Thymidine Kinase Gene Followed by Intravenous Ganciclovir for Recurrent Glioblastoma Multiforme (Summary Last Modified 08/96)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: UCMC-95-3-20-1, NCI-V95-0682
Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation
Phase: Phase II, Phase I
Type: Supportive care
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: P010506, NCT01086735
Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068204, AMC-019, NCT00006264
Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000441214, NCI-05-C-0203, NCI-P6330, NCT00217503
Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 98074, P30CA033572, CHNMC-98074, CDR0000564546, NCT00530218
Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 3 and over
Sponsor: Other
Protocol IDs: CDR0000064947, BUMC-3756, BUSM-FDR001532, NCI-V00-1609, NCT00006340
Gene Therapy in Treating Patients With Primary Brain Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065004, UPCC-3394, NCI-H96-0976, NCT00002824
Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, NHGRI
Protocol IDs: CDR0000067654, NCI-98-C-0140C, NCT00005057
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 09-0744 / 201103095, NCT00871702
Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma
Phase: Phase I
Type: Supportive care, Treatment
Status: Completed
Age: 1 to 17
Sponsor: NCI, Other
Protocol IDs: 1524.00, FHCRC-1524.00, NCI-H00-0065, CDR0000068310, NCT00006480
Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
Phase: No phase specified
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 99061, R01AI058148, P30CA033572, CHNMC-99061, CDR0000600022, NCT00716911
Start Over